EGFR and non-small cell lung carcinoma: The ARCHER1050 study showed that compared with gefitinib, dacomitinib was a better choice for patients with EGFR-mutant NSCLC, which significantly improved patients’ PFS.[11] However, the ARCHER1050 study excluded patients with brain metastases.